兴齐眼药：SQ-24071滴眼液获得临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of SQ-24071 eye drops, which are intended to slow the progression of myopia in children and adolescents [1] Group 1 - SQ-24071 eye drops are classified as a modified new drug of chemical drugs category 2.2 and 2.4 [1] - The company has completed various studies on SQ-24071, including pharmaceutical and non-clinical pharmacology and toxicology, demonstrating good safety and clinical development value [1] - There are currently no similar eye drop formulations available in the domestic and international markets [1]